



Enfermedades Infecciosas y Microbiología Clínica

www.elsevier.es/eimc



Letter to the Editor

How does PrEP work in the real life?



¿Cómo funciona la PrEP en la vida real?

Dear Editor,

We read with interest the article Pre-exposure prophylaxis programme in Madrid Region: two years of experience.¹ The authors carried out an exhaustive analysis of a group of patients included in the post-exposure prophylaxis programme, and the value of their work cannot be questioned in view of the large number of patients and variables included. However, we felt it was missing the analysis of patients who may have had to discontinue treatment for different reasons. It would be interesting to know how many patients were diagnosed with HIV during the treatment, how many suffered deterioration of renal function and, lastly, to have data on adherence. Landovitz et al.² reported a marked decrease in adherence from 96% to 74% during the first three years in the daily treatment group. While there are no doubts about the benefits of PrEP, other data may be needed to better profile the group of patients most likely to reap those benefits.

DOI of original article: <https://doi.org/10.1016/j.eimc.2025.03.003>

References

1. Fernández Piñeiro N, Ayerdi Aguirrebengoa O, Orviz García E, González Pérez C, Vera García M, Puerta López T, et al. Programa de profilaxis pre-exposición de la Comunidad de Madrid: 2 años de experiencia. *Enferm Infecc Microbiol Clin*. 2025;43:133–8.
2. Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, et al. HPTN 083 Study Team, Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. *N Engl J Med*. 2021;385:595–608. <http://dx.doi.org/10.1056/NEJMoa2101016>.

Javier Velasco Montes^{a,*}, María Victoria Pardo Gutiérrez^b,
Carlos Hernando Martín^b, Silvia González Díez^c

^a Departamento de Enfermedades Infecciosas, Hospital San Pedro, Logroño, La Rioja, Spain

^b Servicio de Medicina Interna, Hospital Santos Reyes, Aranda de Duero, Burgos, Spain

^c Atención Primaria, Servicio Riojano de Salud, Logroño, La Rioja, Spain

* Corresponding author.

E-mail address: javier.velasco.montes@hotmail.com (J. Velasco Montes).

<https://doi.org/10.1016/j.eimc.2025.04.003>

2529-993X/ © 2025 Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Published by Elsevier España, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Reply to “How does PrEP work in the real life?”



Respuesta a “¿Cómo funciona la PrEP en la vida real?”

Dear Editor,

We would like to express our gratitude to the authors of the aforementioned letter to the editor, for their interest in our work, for the opportunity to reply that the journal has afforded us.

In our work “Pre-exposure prophylaxis program of the Community of Madrid: 2 years of experience”¹ we analysed the sociodemographic, clinical and behavioural characteristics of the users who were included in the program, examining the variables collected during the initial visits.

We agree on the importance of understanding the reasons for discontinuing HIV pre-exposure prophylaxis, as well as data related to its effectiveness and safety. All the variables studied in the follow-up of HIV pre-exposure prophylaxis users (HIV seroconver-

DOI of refers to article: <https://doi.org/10.1016/j.eimc.2025.04.003>

sion, onset of adverse effects, decreased risk perception, changes in sexual or behavioural practices, lack of adherence to the oral regimen, etc., among others) are ongoing lines of research on which we continue to work. We trust that the analysis of this data, both in our cohort and in others across the country, will help design strategies to identify the profiles at greatest risk of contracting the infection, as well as facilitate proper adherence and retention in the PrEP program, with the goal of preventing further HIV transmission.

Source of funding

We have received no funding to conduct this study. It was carried out during routine care activities.

Declaration of competing interest

The authors declare that they have no conflicts of interest.

Reference

1. Fernández Piñeiro N, Ayerdi Aguirrebengoa O, Orviz García E, González Pérez C, Vera García M, Puerta López T, et al. Programa de profilaxis pre-exposición de la Comunidad de Madrid: 2 años de experiencia. *Enferm Infecc Microbiol Clin*. 2025;43:133–8, <http://dx.doi.org/10.1016/j.eimc.2024.03.014>.

Nuria Fernández Piñeiro^{a,*}, Oskar Ayerdi Aguirrebengoa^b,
Eva Orviz García^b, Cristina González Pérez^a

^a Servicio de Farmacia, Centro Sanitario Sandoval, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain

^b Centro Sanitario Sandoval, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain

* Corresponding author.

E-mail addresses: nur.fernandez87@gmail.com

(N.F. Piñeiro), oskarayerdi@hotmail.com

(O.A. Aguirrebengoa), evaorviz@gmail.com (E.O. García),

cristina.gonzalez.perez@salud.madrid.org (C.G. Pérez).

Received 28 March 2025

<https://doi.org/10.1016/j.eimc.2025.03.015>

2529-993X/ © 2025 Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Published by Elsevier España, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.